Scpharmaceuticals Inc Net Income per Employee (SCPH), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Scpharmaceuticals Inc   (NASDAQ: SCPH)
 

Scpharmaceuticals Inc Net Income per Employee

SCPH's Quarterly Results, Trends, Rankings, Statistics
Scpharmaceuticals Inc recorded a cumulative net loss of $-92 million during 12 month ending in the second quarter 2025.
The Healthcare sector has seen employees of 80 other companies achieving higher income per employee. While Scpharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 2441 to 2747.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCPH Net Income per Employee (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -20,964 -20,750 -19,462 -18,312 -13,861
SCPH's Total Ranking # 2747 # 2441 # 2584 # 2517 # 2483
Seq. Net Income Change - - - - -

SCPH Company Profile >> Back to SCPH Efficiency Comparisons >> Compare SCPH Net Income per Employee to its Competitors

SCPH Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 81
Healthcare Sector # 253
Overall Market # 2747

Net Income per Employee Statistics
High Average Low
$ -1,996 $ -9,744 $ -20,964
(Mar 31 2018)   (Jun 30 2025)




  News about Scpharmaceuticals Inc Income per employee

scPharmaceuticals Secures $125 Million in Non-Dilutive Financing, Empowering its Path to Innovation and Patient-Centric Care,

scPharmaceuticals Secures $75 Million in Non-Dilutive Financing to Support Continued Growth
In a recent press release, scPharmaceuticals, a leading pharmaceutical company specializing in innovative drug delivery solutions, announced that it has successfully secured $75 million in non-dilutive financing through a combination of debt and royalty financings. The financing is provided by Perceptive Advisors, a leading healthcare investment firm, which will not only provide immediate access to $75 million but also allows scPharmaceuticals exclusive access to an additional $50 million, bringing the total funding potential to $125 million.
The additional funding comes at a crucial time for scPharmaceuticals as the company has recorded a cumulative net loss of $50 million during the 12-month period ending in the third quarter of 2023. This financing provides the necessary capital infusion to support the company s ongoing operations, research and development efforts, and commercialization of its pharmaceutical products.




Companies with similar Income per Employee for 12 month ending Jun 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2025Number of Employees Jun 30 2025


Date modified: 2026-08-29T17:39:09+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.